GENPHARMASEC
|
|
| BOM : 531592 NSE : | |
| LT :
Long Term Analysis
Fundamentals : Bad
Valuation : Good [Stock is Cheap] Debt : Low |
Updated: |
| ST :
Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : None or < 25% |
Apr 18,2024 |
|
Price(EOD): ₹ 2.33
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Dyes & Pigments |
| MCap: ₹ 129.01 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GENPHARMASEC | -7% | -46.3% | 7.7% |
| SUDARSHAN CHEMICAL INDUSTRIES | 4.5% | 1.5% | 53.6% |
| VIDHI SPECIALTY FOOD INGREDIENTS | 5.5% | 5.1% | 41.1% |
| KIRI INDUSTRIES | -1% | -23.3% | 10.2% |
| BODAL CHEMICALS | -1.6% | -5.5% | 33.2% |
| BHAGERIA INDUSTRIES | -0.7% | -24.2% | 17% |
| SHREE PUSHKAR CHEMICALS & FERTILISERS | 0% | -12.5% | 9.6% |
| ASAHI SONGWON COLORS | -0.6% | -6.2% | 83.3% |
| PODDAR PIGMENTS | 3.6% | -7.6% | 38.9% |
FUNDAMENTAL ANALYSIS OF GENPHARMASEC
[ Q(TTM): Dec2023, Y: Mar2023
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF GENPHARMASEC
[As on : Apr 18,2024
]
| Ratio | Standalone | |
|---|---|---|
|
P/E P/B P/S |
113.08
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1.14 Cr
[Latest Qtr - Dec2023 - Standalone Results ] 8.42
P/B Calculated based on Book Value of Rs 15.33 Cr
[Latest Year - Mar2023 - Standalone Results ] 4.88
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Dec2023 - Standalone Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
124% -55% -39% |
SHARE PRICE MOMENTUM OF GENPHARMASEC
GENPHARMASEC vs SENSEX
DEBT OF GENPHARMASEC
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2023 2022 2021 Avg_3yrs |
0.2 0 0 0.07 |
- - - - |
|
[Last Annual Data : Mar2023]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF GENPHARMASEC
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Dec2023 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF GENPHARMASEC
| Standalone | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
-18.76% 141.46% -35.56% 785.71% |
-0.33% -92.38% -87.71% -73.73% |
| QtrlyTrend |
-4 | |
| Latest Qtr: Dec2023 | ||
| Quarterly Result Analysis → | ||
GENPHARMASEC related INDICES
No BSE index found!
No NSE index found
You may also like the below Video Courses
FAQ about GENPHARMASEC
Is GENPHARMASEC good for long term investment?
As on Apr 18,2024, the Fundamentals of GENPHARMASEC look Poor and hence it may not be good for long term investment ! See Financial Performance of GENPHARMASEC . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is GENPHARMASEC UnderValued or OverValued?
As on Apr 18,2024, GENPHARMASEC is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of GENPHARMASEC ?
As on Apr 18,2024, the Intrinsic Value of GENPHARMASEC is Rs. 3.84 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 1.04
Fair Value [Median EV / Sales Model] : Rs. 5.21
Fair Value [Median Price / Sales Model] : Rs. 3.84
Estimated Median Fair Value of GENPHARMASEC : Rs. 3.84
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
